GURUJI MEDICAL AGENCY

Viraday tablets contain a combination of three antiretroviral drugs, efavirenz, emtricitabine and tenofovir disoproxil fumarate, which are only effective against RNA viruses (retroviruses) like Human Immunodeficiency Virus (HIV). These three drugs each work by inhibiting the action of the viral-specific enzyme reverse transcriptase (RT) which is needed for the virus to be able to replicate. Retroviruses convert RNA to DNA, which is then integrated into the DNA of infected immune cells so that the virus can replicate. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and acts by binding to a specific site on the RT enzyme and blocks its action in a manner that is noncompetitive with nucleosides, which are the precursors to the building blocks of DNA and RNA. Tenofovir and Emtricitabine are both nucleoside analogue reverse transcriptase inhibitors (NRTI), which means that they block the action of RT by competing with one of the nucleosides needed to transcribe the viral RNA into DNA, becoming incorporated into the chain of newly synthesized viral DNA and preventing it from growing (chain termination). Emtricitabine is an analogue of cytidine and tenofovir is an analogue of adenosine. The combined action of the three antiiretroviral drugs in Viraday tablets prevents the integration of the virus into the DNA of the infected CD4+ immune cell, which inhibits the replication of HIV so that no more virus can be produced and this reduces the viral load (amount of virus). Viraday tablets slow down the replication of HIV within your body but does not kill the virus already incorporated in the CD4+ cells or prevent the spread of the infection to others